{"id":19716,"date":"2022-07-01T08:21:38","date_gmt":"2022-07-01T15:21:38","guid":{"rendered":"https:\/\/marketdepth.com\/?p=19716"},"modified":"2022-07-01T08:21:39","modified_gmt":"2022-07-01T15:21:39","slug":"neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/","title":{"rendered":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study"},"content":{"rendered":"\n

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported<\/a> results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense\u2019s drug for treatment of Alzheimer\u2019s disease. NeuroSense’s biomarker study identified several biomarkers associated with AD, which indicate CogniC’s mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Additionally, hallmarks of AD were detected, such as increased levels of amyloid-\u03b2 (A\u03b2) and intracellular aggregates of tau protein\u00a0among the panel of biomarkers evaluated.<\/p>\n\n\n\n

“Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023.”<\/p>NeuroSense CEO,\u00a0Alon Ben-Noon<\/cite><\/blockquote>\n\n\n\n

NeuroSense is conducting its AD biomarker study via utilization of Neuron-Derived Exosomes (NDE), a cutting-edge technology which allows one to observe key alterations in biomarkers found in the central nervous system in a non-invasive manner via collection of blood samples. Following further analysis, NeuroSense expects to share more detailed results on additional novel biomarkers that were evaluated in this study through scientific conferences and peer-reviewed publications.<\/p>\n","protected":false},"excerpt":{"rendered":"NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense\u2019s drug for treatment of Alzheimer\u2019s disease. NeuroSense’s biomarker study identified several biomarkers associated with AD, which indicate CogniC’s mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation,… View Article<\/a>","protected":false},"author":3,"featured_media":17469,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nNeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense\u2019s drug for treatment of Alzheimer\u2019s disease. NeuroSense’s biomarker study identified several biomarkers associated with AD, which indicate CogniC’s mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation,... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T15:21:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-01T15:21:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/09\/CancerResearch.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study\",\"datePublished\":\"2022-07-01T15:21:38+00:00\",\"dateModified\":\"2022-07-01T15:21:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\",\"url\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\",\"name\":\"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-07-01T15:21:38+00:00\",\"dateModified\":\"2022-07-01T15:21:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/","og_locale":"en_US","og_type":"article","og_title":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth","og_description":"NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense\u2019s drug for treatment of Alzheimer\u2019s disease. NeuroSense’s biomarker study identified several biomarkers associated with AD, which indicate CogniC’s mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation,... View Article","og_url":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-07-01T15:21:38+00:00","article_modified_time":"2022-07-01T15:21:39+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/09\/CancerResearch.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study","datePublished":"2022-07-01T15:21:38+00:00","dateModified":"2022-07-01T15:21:39+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/","url":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/","name":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-07-01T15:21:38+00:00","dateModified":"2022-07-01T15:21:39+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/neurosense-reports-positive-preliminary-results-from-alzheimers-biomarker-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"NeuroSense Reports Positive Preliminary Results from Alzheimer\u2019s Biomarker Study"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19716"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=19716"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19716\/revisions"}],"predecessor-version":[{"id":19717,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/19716\/revisions\/19717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/17469"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=19716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=19716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=19716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}